Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Metadoxine in Patients with Metabolic-associated Steatotic Liver Disease
TCTR20250326003Phase 1Not yet recruiting
- Sponsor
- Pacific Healthcare
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in Metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Metadoxine with Placebo (2 arms). Planned start Apr 2025; status: not yet recruiting.
02
Drugs
Metadoxine
03
Conditions
Metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on TCTR20250326003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250326003.